SynthesisProstate cancer and prostatic diseases2022
Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis.
Synthesis in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2024Pooled it
- Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review.Nutrients · 2024Pooled it
- Does Androgen Deprivation for Prostate Cancer Affect Normal Adaptation to Resistance Exercise?International journal of environmental research and public health · 2022Pooled it
- The underexplored links between cancer and the internal body climate: Implications for cancer prevention and treatment.Frontiers in oncology · 2022Pooled it
- Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study.Journal of the National Cancer Institute · 2025Trial
- Is Exercise During Androgen Deprivation Therapy Effective and Safe? A Randomized Controlled Trial.Scandinavian journal of medicine & science in sports · 2025Trial
- Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177-PSMA-617.The oncologist · 2026Article
- Muscle mitochondria, function, mass, and quality of life in prostate cancer during androgen deprivation therapy.Nature communications · 2026Article
- Subcutaneous adipose tissue outperforms muscle strength as an indicator of survival and quality of life in patients with cancer: a multicenter cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Weight-related changes in MRI-derived measures of body composition and liver steatosis: a large-scale analysis for obesity trial design.International journal of obesity (2005) · 2026Article
- MRI evaluation of obturator internus muscle: its relationship with body composition and prognostic implications in prostate cancer patients undergoing ADT.European radiology · 2026Article
- Review
- Automated volumetric MRI quantification of body fat and skeletal muscle in the UK Biobank: technical validation against expert manual segmentations and comparison with single-slice techniques.Abdominal radiology (New York) · 2026Article
- Impact of combined skeletal muscle index, subcutaneous fat index, and visceral fat index on prognosis in non-metastatic non-small cell lung cancer.BMC pulmonary medicine · 2026Observational
- A Pilot Feasibility Study of a Group-Based Remote-Delivered Dyadic Exercise Intervention in Hispanic Men With Prostate Cancer and Their Caregivers.Cancer medicine · 2026Article
- Prognostic value of body composition out of PSMA-PET/CT in prostate cancer patients undergoing PSMA-therapy.European journal of nuclear medicine and molecular imaging · 2025Article
- Investigating the effect of the family-centered empowerment model on the weight and self-concept of obese boys.BMC psychology · 2025Article
- Optimization-Incorporated Deep Learning Strategy to Automate L3 Slice Detection and Abdominal Segmentation in Computed Tomography.Bioengineering (Basel, Switzerland) · 2025Article
- Effect of subcutaneous fat on long-term survival after surgery for stage I-III breast cancer as determined by computed tomography.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo systematically review and analyse the associations between fat and muscle mass measures with overall survival in men with prostate cancer.
methodsA systematic search was conducted in CINAHL, Cochrane Library, EMBASE, PubMed, and Web of Science databases from inception to December 2020, while abstracts from the American Society of Clinical Oncology (ASCO), Clinical Oncology Society of Australia (COSA), and the American College of Sports Medicine (ACSM) conferences were searched from 2014 to 2020. Eligible articles examined the association of body composition measures, such as fat mass (e.g., fat mass, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and VAT/SAT) and muscle mass measures, with overall survival in prostate cancer patients at any treatment stage. The primary endpoint was overall survival. Random-effect meta-analysis was conducted for studies reporting multivariable or univariable analysis assessing the associations of fat mass measures (i.e., fat mass, VAT, SAT, VAT/SAT) and muscle mass measures with overall survival.
resultsSixteen cohort studies that comprised 4807 men with prostate cancer were included. Total adiposity (hazard ratio (HR) 0.98, 95% CI: 0.75-1.28, p = 0.888) and VAT (HR 1.03, 95% CI: 0.74-1.43, p = 0.873) were not significantly associated with overall survival, while higher subcutaneous adipose tissue levels were associated with higher survival (HR 0.68, 95% CI: 0.54-0.84, p = 0.001). Greater mortality risk was found in patients with localised (HR 1.91, 95% CI: 1.40-2.62, p < 0.001) and advanced disease (HR 1.43, 95% CI: 1.07-1.92, p = 0.020) presenting with low levels of muscle mass compared to those presenting with high levels. DISCUSSION: These results indicate that although overall adiposity should be cautiously interpreted in regards to survival, high muscle mass and SAT, and low VAT/SAT ratio values are associated with overall survival in men with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.